×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)

Milestone Pharmaceuticals Stock Forecast, Price & News

$6.07
+0.21 (+3.58%)
(As of 07/5/2022 04:00 PM ET)
Add
Compare
Today's Range
$5.76
$6.27
50-Day Range
$5.13
$6.69
52-Week Range
$3.98
$8.24
Volume
10,239 shs
Average Volume
25,095 shs
Market Capitalization
$181.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Milestone Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
69.2% Upside
$10.00 Price Target
Short Interest
Bearish
10.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$28,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.44) to ($1.60) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.04 out of 5 stars

Medical Sector

463rd out of 1,428 stocks

Pharmaceutical Preparations Industry

217th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MIST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Milestone Pharmaceuticals logo

About Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

MIST Stock News Headlines

Milestone Pharmaceuticals GAAP EPS of -$0.33
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MIST
Fax
N/A
Employees
29
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/05/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+64.7%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-42,850,000.00
Pretax Margin
-295.64%

Debt

Sales & Book Value

Annual Sales
$15 million
Book Value
$3.77 per share

Miscellaneous

Free Float
28,240,000
Market Cap
$181.61 million
Optionable
Not Optionable
Beta
2.81














Milestone Pharmaceuticals Frequently Asked Questions

Should I buy or sell Milestone Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Milestone Pharmaceuticals stock.
View analyst ratings for Milestone Pharmaceuticals
or view top-rated stocks.

What is Milestone Pharmaceuticals' stock price forecast for 2022?

2 Wall Street research analysts have issued 12 month price objectives for Milestone Pharmaceuticals' shares. Their MIST stock forecasts range from $10.00 to $10.00. On average, they expect Milestone Pharmaceuticals' share price to reach $10.00 in the next year. This suggests a possible upside of 64.7% from the stock's current price.
View analysts' price targets for Milestone Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Milestone Pharmaceuticals' stock performed in 2022?

Milestone Pharmaceuticals' stock was trading at $6.55 at the start of the year. Since then, MIST shares have decreased by 7.3% and is now trading at $6.07.
View the best growth stocks for 2022 here
.

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Milestone Pharmaceuticals
.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its earnings results on Thursday, May, 12th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.06.
View Milestone Pharmaceuticals' earnings history
.

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the following people:
  • Mr. Joseph G. Oliveto M.B.A., CEO, Pres & Director (Age 54, Pay $908.14k)
  • Mr. Amit Hasija, CFO & Exec. VP of Corp. Devel. (Age 49, Pay $605.78k)
  • Dr. Francis Plat FAHA, M.D., Chief Scientific Officer (Age 63, Pay $586.12k)
  • Dr. Philippe Douville, Founder, Strategic Advisor & Member of Scientific Advisory Board (Age 60)
  • Mr. Jeff Nelson, Chief Operating Officer
  • Dr. Philip T. Sager FACC, FAHA, FHRS, M.D., Chief Medical Advisor & Member of the Scientific Advisory Board (Age 66)
  • Dr. Guy Rousseau, SVP of Regulatory Affairs and Quality Management
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 58)
  • Dr. David B. Bharucha FACC, M.D., Ph.D., Chief Medical Officer (Age 60)

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $6.07.

How much money does Milestone Pharmaceuticals make?

Milestone Pharmaceuticals (NASDAQ:MIST) has a market capitalization of $181.61 million and generates $15 million in revenue each year. The company earns $-42,850,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Milestone Pharmaceuticals have?

Milestone Pharmaceuticals employs 29 workers across the globe.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The official website for Milestone Pharmaceuticals is www.milestonepharma.com. The company can be reached via phone at (514) 336-0444 or via email at ir@milestonepharma.com.

This page (NASDAQ:MIST) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.